NO945045L - Höykonsentrert immunglobulinpreparat og fremgangsmåte for dets fremstilling - Google Patents

Höykonsentrert immunglobulinpreparat og fremgangsmåte for dets fremstilling

Info

Publication number
NO945045L
NO945045L NO945045A NO945045A NO945045L NO 945045 L NO945045 L NO 945045L NO 945045 A NO945045 A NO 945045A NO 945045 A NO945045 A NO 945045A NO 945045 L NO945045 L NO 945045L
Authority
NO
Norway
Prior art keywords
preparation
highly concentrated
concentrated immunoglobulin
immunoglobulin
immunoglobulin preparation
Prior art date
Application number
NO945045A
Other languages
English (en)
Other versions
NO945045D0 (no
NO315260B1 (no
Inventor
Johann Eibl
Yendra Linnau
Wolfgang Teschner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6506449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO945045(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of NO945045D0 publication Critical patent/NO945045D0/no
Publication of NO945045L publication Critical patent/NO945045L/no
Publication of NO315260B1 publication Critical patent/NO315260B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19945045A 1993-12-28 1994-12-27 Höykonsentrert immunglobulinpreparat og fremgangsmåte for dets fremstilling NO315260B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4344824A DE4344824C1 (de) 1993-12-28 1993-12-28 Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung

Publications (3)

Publication Number Publication Date
NO945045D0 NO945045D0 (no) 1994-12-27
NO945045L true NO945045L (no) 1995-06-29
NO315260B1 NO315260B1 (no) 2003-08-11

Family

ID=6506449

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19945045A NO315260B1 (no) 1993-12-28 1994-12-27 Höykonsentrert immunglobulinpreparat og fremgangsmåte for dets fremstilling

Country Status (15)

Country Link
US (1) US5608038A (no)
EP (1) EP0661060B1 (no)
JP (1) JP3040678B2 (no)
AT (2) AT407707B (no)
CA (1) CA2138853A1 (no)
CZ (1) CZ284186B6 (no)
DE (2) DE4344824C1 (no)
DK (1) DK0661060T3 (no)
ES (1) ES2158877T3 (no)
FI (1) FI111224B (no)
HR (1) HRP941018B1 (no)
HU (1) HU220766B1 (no)
NO (1) NO315260B1 (no)
RU (1) RU2104713C1 (no)
YU (1) YU77994A (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CN1151842C (zh) * 1995-07-27 2004-06-02 基因技术股份有限公司 稳定等渗的冻干蛋白制剂
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
JP3919235B2 (ja) * 1997-06-13 2007-05-23 ジェネンテク，インコーポレイテッド 抗体製剤
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
ES2332402T5 (es) * 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CA2490423A1 (en) * 2002-06-21 2003-12-31 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
SI2335725T1 (sl) * 2003-04-04 2017-01-31 Genentech, Inc. Visokokoncentrirane formulacije protiteles in proteinov
MX2007000891A (es) * 2004-07-23 2007-04-18 Genentech Inc Cristalizacion de anticuerpos o fragmentos de ellos.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
TWI489994B (zh) * 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US20100172862A1 (en) * 2008-11-28 2010-07-08 Abbott Laboratories Stable antibody compositions and methods of stabilizing same
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
SG174258A1 (en) * 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
MX2012010198A (es) 2010-03-01 2012-10-03 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi).
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
RU2675824C2 (ru) 2013-09-11 2018-12-25 Игл Байолоджикс, Инк. Жидкие белковые составы, содержащие ионные жидкости
ES2875878T3 (es) 2013-11-18 2021-11-11 Formycon Ag Composición farmacéutica de un anticuerpo anti-VEGF
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
RU2599029C1 (ru) * 2015-07-16 2016-10-10 Игорь Геннадьевич Ковшик Химерный иммуноглобулиновый препарат, обладающий специфическим противовирусным или антибактериальным действием
LT3334747T (lt) 2015-08-13 2023-12-27 Amgen Inc. Įkrautas giluminis antigeną surišančio baltymo filtravimas
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075193A (en) * 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
AT359641B (de) * 1978-09-19 1980-11-25 Immuno Ag Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates
US4186192A (en) * 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
JPS57203017A (en) * 1981-06-09 1982-12-13 Fujirebio Inc Purifying method of immunoglobulin
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
DK166763B1 (da) * 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
EP0168506B2 (en) * 1984-07-07 1998-01-07 Armour Pharma GmbH Process for preparing gamma globulin suitable for intravenous administration
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
US5248767A (en) * 1986-06-11 1993-09-28 Behringwerke Aktiengesellschaft Process for the preparation of a pasteurized immunoglobulin preparation using ethanol
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
CH684164A5 (de) * 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.

Also Published As

Publication number Publication date
DE59409761D1 (de) 2001-06-28
CA2138853A1 (en) 1995-06-29
US5608038A (en) 1997-03-04
HU220766B1 (hu) 2002-05-28
HRP941018A2 (en) 1997-04-30
HUT70449A (en) 1995-10-30
ATE201328T1 (de) 2001-06-15
CZ328494A3 (en) 1995-07-12
CZ284186B6 (cs) 1998-09-16
HRP941018B1 (en) 1999-12-31
EP0661060A3 (de) 1997-01-15
ES2158877T3 (es) 2001-09-16
RU2104713C1 (ru) 1998-02-20
YU77994A (sh) 1997-03-07
JP3040678B2 (ja) 2000-05-15
EP0661060B1 (de) 2001-05-23
HU9403795D0 (en) 1995-02-28
FI946104A0 (fi) 1994-12-27
JPH07206709A (ja) 1995-08-08
DE4344824C1 (de) 1995-08-31
EP0661060A2 (de) 1995-07-05
NO945045D0 (no) 1994-12-27
NO315260B1 (no) 2003-08-11
FI946104A (fi) 1995-06-29
AT407707B (de) 2001-05-25
FI111224B (fi) 2003-06-30
DK0661060T3 (da) 2001-07-30
ATA237894A (de) 2000-10-15

Similar Documents

Publication Publication Date Title
NO945045L (no) Höykonsentrert immunglobulinpreparat og fremgangsmåte for dets fremstilling
IS4185A (is) Hliðstæð aðferð til framleiðslu fenýlsúlfonylamino-pýrimidines afleiða
YU47204B (sh) Derivati didehidro-vitamina d3
DE3782525T2 (de) Aryl-substituierte(n-piperidinyl)methyl und (n-piperazinyl)methylazole mit antipsychotischer wirkung.
PL314187A1 (en) Novel derivatives of pyrazine carboxamide, method of obtaining them and their application in pharmaceutical composition
ES2074846T3 (es) Nuevas naftil-etil-ureas y naftil-etil-tioureas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
ES2072784T3 (es) Benzo- y piridopiridonas substituidas con sulfonilbencilo.
DE69434356D1 (de) Inclusion-Komplex von Beta-Cyclodextrin mit Diclofenac
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
YU46914B (sh) Metoksimetilna jedinjenja
ATE236942T1 (de) Niedrigviskose polyisocyanatmischung
PT87563A (pt) Process for the preparation of vinylcephalosporins useful as medicaments
ES2021334B3 (es) Composiciones de caucho que contienen derivados aminicos del 1,3,4-triadiazol.
ES2014445B3 (es) Composiciones farmaceuticas que contienen compuestos 5-fenil-1,3-dioxialquenilicos.
FR2675667B1 (fr) Agent edulcorant derivant a l'acide l-aspartique ou l-glutamique; son procede de preparation.
KR890003380A (ko) 피부에 축적하는 외용의 항 바이러스성 약학적 조성물 및 그 제조방법
AU7610194A (en) Thiocarbamoyl compounds used as antimicrobial agents
TW362019B (en) Stable preparation of sodium 1,4-dimethylisopropylazulene-3-sulfonate and process thereof
HUT35652A (en) Process for production of veterinary composition containing sulphamids suitable against illnesses caused by pathogene coli stocks
IT1265430B1 (it) Derivati del pirrolo e loro impieghi
KR870008535A (ko) "밤"가루(율분)
YU47111B (sh) Jedinjenje hroma i postupak za izradu hromnih jedinjenja
KR920019470A (ko) 할라이드와 계면활성제를 첨가하지 않은 납땜공정에 사용하는 무세척 후락스 조성물
KR920008178A (ko) 탁주 조성물
KR840003810A (ko) 스프레이용 방취.방미 조성물

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees